In mouse tumor models, Scd-1 inhibitors synergistically enhanced the anti-tumor effects of anti-PD-1 antibody therapy and CAR-T cell therapy(Katoh et al., 2022; Sugi et al., 2023). This evidence concerns the gene SCD and neoplasm.